Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088647 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating MST-997 in Advanced Malignant Solid Tumors
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00088647: Clinical Trial Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00088647 is a Phase 1 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088647, a Phase 1 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid tumors.
Interventions
- DRUG MST-997
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Why NCT00088647 stopped before completion
NCT00088647 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which MST-997 is the first listed.
NCT00088647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00088647 about?
NCT00088647 is a clinical study titled "Study Evaluating MST-997 in Advanced Malignant Solid Tumors". The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid tumors.
What is the current status of trial NCT00088647?
This trial is currently terminated. It is a Phase 1 study.
What interventions are being tested in trial NCT00088647?
The interventions under investigation include: MST-997 (DRUG).
Who is sponsoring clinical trial NCT00088647?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.